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Abstract We have explored the possibilities of using human
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) as a
single immunoglobulin fold-based scaffold for the generation of
novel binding ligands. To obtain a suitable protein library
selection system, the extracellular domain of CTLA-4 was first
displayed on the surface of a filamentous phage as a fusion
product of the phage coat protein p3. CTLA-4 was shown to be
functionally intact by binding to its natural ligands B7-1 (CD80)
and B7-2 (CD86) both in vitro and in situ. Secondly, the
complementarity determining region 3 (CDR3) loop of the
CTLA-4 extracellular domain was evaluated as a permissive site.
We replaced the nine amino acid CDR3-like loop of CTLA-4
with the sequence XXX-RGD-XXX (where X represents any
amino acid). Using phage display we selected several CTLA-4-
based variants capable of binding to human KvL3 integrin, one of
which showed binding to integrins in situ. To explore the
construction of bispecific molecules we also evaluated one other
potential permissive site diametrically opposite the natural CDR-
like loops, which was found to be tolerant of peptide insertion.
Our data suggest that CTLA-4 is a suitable human scaffold for
engineering single-domain molecules with one or possibly more
binding specificities. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
Key words: Cytotoxic T lymphocyte-associated antigen 4;
Phage display; Sca¡old; Integrin
1. Introduction
Antibodies are the evolutionary solution to nature’s re-
quirement for binding ligands to combat disease. The immune
system is composed of a huge repertoire of antibodies with
diverse molecular surfaces, which are capable of recognizing
essentially any antigen. The generation of small recombinant
versions of antibodies is of fundamental importance to the
¢eld of targeted therapy and imaging [1,2]. Signi¢cant advan-
ces in this ¢eld have been made using protein engineering and
display technologies, which allow the rapid isolation of re-
combinant antigen-speci¢c antibodies in vitro. Large ‘single
pot’ repertoires of recombinant antibody fragments have
been generated, pre-dominantly using ¢lamentous phage as
the display vehicle [3] which provide a source of recombinant
single-chain Fv or Fab fragments to any chosen target [4^6].
Despite single chain Fv antibodies (scFv) and Fab antibod-
ies being the most frequently used binding ligands, they can be
seen to have certain disadvantages. Firstly, they are composed
of two domains, which require complicated cloning schedules
for the pairing of antibody variable genes and in some cases
may lead to the unstable association of the two polypeptide
chains. Secondly, the restraining of randomized peptide se-
quences is complicated by the fact that immunoglobulins
(Igs) carry six variable loops brought into close proximity
by the association of two separate domains. It is apparent
that simpler molecular sca¡olds, based on a single domain,
may o¡er potential advantages for combinatorial library en-
gineering.
E¡orts to study single Ig-domain molecules as binding li-
gands initially focused on the production of single VH (vari-
able region of an antibody heavy chain) domains [7]. How-
ever, these molecules generally have a tendency to aggregate
due to the exposed hydrophobic surface normally buried at
the VH/VL (variable region of an antibody light chain) inter-
face [8,9]. There are, however naturally occurring single do-
main molecules based on the immunoglobulin VHH domain
from camelids, which are devoid of light chains [10]. Initial
problems with the production of human single VH domains
have been addressed by ‘camelizing’ which involves mimicking
residues in the naturally occurring single domain camel VHH
antibodies on a human framework [11]. A number of novel
single domain sca¡olds have been described which have a
de¢ned structure in which permissive sites have been identi-
¢ed. These include protein Z, tendamistat (for a review see
[12]), ¢bronectin [13] and lipocalin [14]. The properties of a
sca¡old which could be deemed important are that it should;
(i) be human if therapeutic applications are envisaged; (ii) be
a small single domain molecule and be amenable to engineer-
ing into multivalent or multispeci¢c molecules; (iii) have a
known three-dimensional structure to allow easy loop model-
ing; (iv) fold correctly and be stable both in vitro and in vivo
and (v) have permissive site(s)/surfaces for introducing diver-
sity which are su⁄ciently large for high a⁄nity binding and
which have the potential to be a⁄nity/speci¢city matured.
The Ig protein fold has been used by nature to solve many
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of the requirements of biomolecular recognition. The Ig fold
occurs in functionally diverse proteins which includes matrix
proteins, receptors, chaperones, enzymes and of course anti-
bodies (for a review see [15]). In searching for a small human
molecule based on an Ig fold that will be amenable to engi-
neering of its ligand binding site, we have evaluated cytotoxic
T lymphocyte-associated antigen 4 (CTLA-4) [16,17]. CTLA-4
is normally present on the surface of T-cells and mediates
their activity by interactions with its co-receptors B7-1 and
B7-2 on antigen-presenting cells [18].
In contrast to Igs, the CTLA-4 extracellular domain has
two intra-molecular disul¢de bridges and can exist as a single
domain. Albeit, on the surface of T-cells it exists pre-domi-
nantly as a disul¢de-bridged homodimer [19,20]. The produc-
tion of monomeric CTLA-4 extracellular domain has been
reported previously [20,21] and required the removal of the
C-terminal cysteine residue employed in the dimerization on
the surface of T-cells. The three dimensional structure of
CTLA-4 has recently been elucidated [22] and has con¢rmed
that despite dimerization on the surface of T-cells, CTLA-4
exists essentially as two single domain molecules which do not
interact with each other via a hydrophobic face as is the case
for Fv-type molecules. The existence of three naturally occur-
ring loops analogous to complementarity determining region
(CDR) loops present in Igs suggests that it would be structur-
ally feasible to replace these loops with heterologous sequen-
ces.
In this study we have generated a phage displayed reper-
toire of CTLA-4 variants in which the CDR3-like loop has
been replaced by an RGD motif which mediates binding to
integrin, presented at the apex of a randomized sequence.
From this repertoire CTLA-4 variants speci¢c for KvL3 integ-
rin were selected. Furthermore, with the aim of building bi-
speci¢c single Ig-domains, a loop opposite the natural binding
surface of CTLA-4 was also investigated as a potential per-
missive site.
2. Materials and methods
2.1. Construction of a recombinant CTLA-4 sca¡old molecule, mutant
derivatives and repertoires for display on ¢lamentous phage
The sequence corresponding to the extracellular part of the human
CTLA-4 (residue A1MHV^DPEP120) minus the C-terminal cysteine
residue (C121) was cloned into the phage display vector pCES-1 [6].
Human CTLA-4 was ampli¢ed by polymerase chain reaction (PCR)
from 0.1 ng of pBSK(+)hCTLA-4 (Innogenetics, Gent, Belgium)
using primers CTLA-4 (reverse) (5P-GGCATGCAATGCAGTGCA-
CAGGCAATGCACGTGGCCCAGCCTGCT-3P) and CTLA-4 (for-
ward) (5P-GCCGCAGTTGCAAGCGGCCGCCGGTTCTGGATC-
AA TTACATAAAT-3P) to append ApaL1 and Not1 restriction sites.
The PCR product was cloned into pCES-1 and transformed into the
Escherichia coli strain TG1.
The SGGGS sequence was inserted into the loop APB (L strands are
designated according to [22]) between S14R. The pCES-1 CTLA-4
template was ampli¢ed using primers #11209 (5PGATTACGCCA-
AGCTTTGGAGC-3P) and #11071 (5P GTCACCACGAG AGC-
CACCGCCACCGCTGCTGGCCAGTACCACAG-3P) which ampli-
¢es the 5P end of the CTLA-4 gene. A second PCR was performed
using primers # 11072 (5P-CGTGGT GACGGTGGCGGTGGC-
TCTCG AGGCATCGCCAGCTTTG-3P) and #11210 (5P-ATGCG-
GCCCCATTCAGATC-3P) which ampli¢es the 3Pend of the CTLA-
4 gene. Both products were gel puri¢ed and an additional PCR with
primers #11209 and #11210 was performed. The resulting PCR frag-
ment was digested with ApaL1 and Not1 and cloned into pCES-1
CTLA-4 to give pCES-1 CTLA-4 (APB).
For the construction of a CTLA-4 (X3-RGD-X3) repertoire, a frag-
ment corresponding to CTLA-4 was recovered as an ApaL1/Not1
fragment and was subjected to PCR with oligonucleotides CTLA-4
(reverse) and CTLA-4 (RGD) (5P-AATCTGGGTT CCGTTGC-
CTATGCCMNNMNNMNNATCGCCACGMNNMNNMNNCTC-
CACCTTGCAGATGTAGAG-3P). The PCR product was then puri-
¢ed and reampli¢ed with CTLA-4 (reverse) and CTLA-4 (AMP) (5P-
GCGGCCGCCGGTTCTGGATCAATTAC ATAAATCTGGGTT-
CCGTTGCC-3P). This fragment DNA was puri¢ed, digested with
ApaL1 and Not1, cloned into pCES-1 and transformed into E. coli
TG1. All CTLA-4 sca¡old derivatives were con¢rmed by DNA se-
quencing.
2.2. Selection of phage displayed CTLA-4 RGD repertoire
Immunotubes (Nunc) were coated overnight at 4‡C with 10 Wg/ml
of KvL3 integrin (Chemikon) in coating bu¡er (0.1 M carbonate bu¡-
er, pH 9.6). After three washes with phosphate-bu¡ered saline (PBS;
0.15 M NaCl, 8 mM Na2HPO4 and 1.56 mM KH2PO4, pH 7.4) tubes
were blocked with 2% dried skimmed milk in PBS (2% M-PBS) for 1^
2 h at room temperature. Selection of the (X3-RGD-X3) repertoire
was performed as in [6].
2.3. Screening of selected clones by bacteriophage and soluble
enzyme-linked immunosorbent assay (ELISA)
Clones from the second and third round of selection were picked
randomly and both soluble molecules and phage displayed molecules
were produced as described previously [5].
For initial detection of positive binding phage clones, ELISA plates
were coated with 1 Wg/ml KvL3 integrin (Chemikon), 1Wg/ml B7.1 Ig
(Innogenetics) and 1 Wg/ml bovine serum albumin (BSA) and incu-
bated overnight at 4‡C in coating bu¡er. To test for binding to B7,
ELISA was performed on B7-1 Ig, B7-2 Ig (B7 fused to Fc fragment)
and B7-2 His (B7.2 fused to histidine tag), puri¢ed from baculovirus
(Innogenetics) and coated onto ELISA plates at 5 Wg/ml. Screening of
soluble CTLA-4-derived molecules was performed in 96 well ELISA
plates coated with antigens B7-1 Ig (1 Wg/ml), KvL3 integrin (1 Wg/ml),
B7-2 Ig (1Wg/ml) and B7-2 His (10Wg/ml) as in [5].
2.4. Protein puri¢cation sodium dodecyl sulfate^polyacrylamide gel
electrophoresis (SDS^PAGE) and Western blot analysis
Protein samples were analyzed by SDS^PAGE through 12.5% Tris/
glycine gels. Samples for Western blotting analysis were transferred to
nitrocellulose membranes. Prior to immunostaining, blots were incu-
bated with PBS plus 0.1% Tween and 2% non-fat milk powder
(M-PBST). Antibodies for immunoblotting were diluted in M-PBST
to 1 Wg/ml for the anti-CTLA-4 antibody (Innogenetics) and 1:2000
for anti c-Myc. Membranes were washed with PBS and PBS plus 0.1%
Tween and visualized using staining with diamino benzidine (0.5 mg/
ml diamino benzidine in 0.05 M Tris pH 7.6 and 0.015% H2O2).
Puri¢ed proteins were prepared as in [5] and analyzed on a pre-
calibrated Superdex 75 column (Pharmacia) on a Bio-Logic HPLC
machine (BioRad). Fractions were collected and stored at 320‡C
for further analysis.
2.5. Binding of phage CTLA-4 derivatives to cells by £ow cytometry
The binding of phage displaying CTLA-4 and CTLA-4 sca¡old
derivatives was measured by £ow cytometry (Becton Dickinson, Ox-
nard, USA). The EBV-transformed cell line RPMI 8866 (Innoge-
netics) was used to test binding of wild-type CTLA-4 phage to cells
expressing B7-1 and B7-2. About 500 000 cells were used per experi-
ment. Cells were washed once in PBS and resuspended in 2% M-PBS
plus 0.1% BSA and 0.01% azide. To test the binding of phage dis-
playing CTLA-4 RGD sca¡old derivatives to cell surface integrins we
used £ow cytometric analysis of human umbilical vein endothelial
cells (HUVECS) [23].
3. Results
3.1. Display of the extracellular domain of human CTLA-4 on
the surface of ¢lamentous phage
We displayed the extracellular domain of CTLA-4 on the
surface of ¢lamentous phage. We used the variant from
A1MHV to DPEP120 (numbered according to [20]) minus
C121, which is required for dimer formation on the surface
of T-cells, fused to the N-terminus of the phage coat protein
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p3. Fig. 1a shows the phagemid CTLA-4 vector construct.
The recent report by Nuttall et al. (1999) describing CTLA-
4 as a sca¡old molecule for the presentation of somatostatin
describes a slightly shorter sca¡old molecule from A1MHV to
QIYV115 [24]. We have found that the inclusion of an extra
¢ve residues of the CTLA-4 extracellular domain has not
a¡ected the ability to display functional molecules on phage.
ELISA with this CTLA-4 phage showed speci¢c binding to
B7-1 Ig and B7-2 Ig, furthermore, the signal decreased pro-
portionally with the amount of phage present (Fig. 1b). Bind-
ing of soluble CTLA-4 product could also be seen in ELISA
(data not shown). Further evidence of ligand-speci¢c binding
was shown by competition with soluble B7-1 Ig and B7-2 His
(puri¢ed recombinant B7-2 having a histidine puri¢cation tag
rather than an Fc) in ELISA (data not shown). This clearly
demonstrated that CTLA-4 was displayed on phage and was
correctly folded for recognition of its natural ligands B7-1 and
B7-2. Immunoblotting showed a soluble product of the ex-
pected size of 16 kDa, detected using both antibodies to the
c-myc epitope tag and a monoclonal antibody to CTLA-4
(data not shown, Fig. 5). A further con¢rmation of the high
speci¢city of the CTLA-4 sca¡old molecule was shown by
binding to cells transfected with B7-1 and B7-2. Phage dis-
playing the CTLA-4 extracellular domain showed strong
binding whereas only background binding was seen with
wild-type phage particles (Fig. 1c). Thus CTLA-4, despite
being a glycoprotein in eukaryotic cells, can be expressed in
a non-glycosylated form in E. coli and be functionally dis-
played by bacteriophage.
3.2. Design of a CTLA-4 sca¡old library with a propensity to
bind integrins
Both sequence alignment and structural analysis showed
CTLA-4 to be most similar to Ig superfamily variable do-
mains, with eight L strands providing the framework for three
complementarity determining region-like loops, CDR1, CDR2
and CDR3 [22] (Fig. 2). We predicted that these loops would
be ideal permissive sites for randomization and that the
underlying protein framework containing two disul¢de
bridges would be su⁄ciently stable to accommodate amino
acid changes. As a proof of concept we randomized the
CDR3 loop of CTLA-4 (L97MYPPPYYL105) since mutational
analysis had shown this loop as being almost exclusively re-
sponsible for binding to the natural ligands B7-1 and B7-2
[17]. We chose to replace the CDR3 of CTLA-4 with the
RGD motif, which is known to be essential for binding to
KvL3 integrin [25], at the apex of a randomized loop. We
replaced the nine amino acids of the CDR3-like loop of
CTLA-4 (L97MYPPPYYL105) with XXX-RGD-XXX, where
X represents any amino acid and X being encoded by (NNK)
at the nucleotide level. Mutagenesis was restricted to nine
amino acids to respect the sequence similarity to the natural
Fig. 1. Functional display of CTLA-4 extracellular domain. a: A
¢gure of the phagemid vector construct displaying the extracellular
domain of CTLA-4 from A1MHV to DPEP120, the backbone vector
is pCES-1 [6] which contains the following features: antibody genes
CH1 and CU of the constant heavy and light chains; PlacZ, pro-
moter; rbs, ribosome binding site; S, signal sequence; H6, six histi-
dines; tag, c-myc-derived tag; amber, amber codon that allows pro-
duction of soluble Fab fragments in non-suppressor strains, gIII,
gene encoding one of the minor coat proteins of ¢lamentous phage.
Restriction sites used for cloning are indicated. b: Binding of phage
displaying the CTLA-4 sca¡old is shown binding to its natural li-
gands B7-1 Ig (F) and B7-2 Ig (b) but not to the non-relevant anti-
gen, BSA (8). A graph of log (phage/well) versus absorbance at
450 nm is shown. Strong speci¢c binding is seen decreasing propor-
tionately with the amount of phage present (c). Binding of phage
(5U1011 cfu/ml) displaying CTLA-4 to B7-1 and B7-2 present on a
cell membrane. Flow cytometry on RPMI 8866, that strongly ex-
presses both B7-1 and B7-2 is shown. The results show binding of
wild-type CTLA-4 sca¡old displaying phage (bold line) whereas
phage derived from empty pCES-1 (thin line) showed non-speci¢c
binding and cells with only control showed auto£uorescence (dotted
line).
Table 1
Panning of the phage displayed CTLA-4-RGD sca¡old library on KvL3 integrin
Selection round Input phagea Output phagea Input/output Enrichment factor
(fold)
Percentage binders
(KvL3)
Percentage binders
(B7-1 Ig)
1 1e13 6.9e4 6.9a39 ^ nd nd
2 1.9e13 3.1e5 1.6e38 2.3 0 0
3 1.8e13 2.2e6 1.6e37 10 65 0
nd: not determined.
aThe input and output phage titrations are given as colony forming units (cfu).
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CDR3-like loop. Based on this design, oligonucleotides were
used to build a CTLA-4 (X3-RGD-X3) repertoire of 1.3U107
independent clones.
3.3. Selection of a phage displayed CTLA-4 (X3-RGD-X3)
sca¡old repertoire
The CTLA-4 sca¡old repertoire was selected on puri¢ed
human KvL3 integrin. After three rounds of selection, 65%
of clones showed binding to KvL3 integrin with no detectable
binding to B7-1 Ig or BSA (Table 1). Twelve binding clones
were sequenced, revealing six di¡erent peptides in which the
CDR3 (L97MYPPPYYL105) sequence was replaced by the
RGD motif £anked by selected sequences (Table 2). Clone
RGD-7B was the dominant clone being recovered ¢ve times,
followed by clone RGD-8H which was recovered three times,
all other clones were identi¢ed once in the group sequenced.
Clone RGD-7B showed binding as a soluble product in our
high throughput screening ELISA. We reasoned that this
clone was our optimum binding clone for further analysis,
as the other ¢ve clones did not give binding in this assay of
low sensitivity (data not shown).
The clones RGD-8H, RGD-9B, RGD-8E and RGD-11B
contained the RGD motif presented as expected, £anked by
three di¡erent selected amino acids on either side. The clones,
RGD-7B and RGD-11C, contained an RGD motif £anked by
three selected amino acid residues on the 5P side (of the RGD
sequence) and ¢ve selected residues on the 3P side (of the
RGD motif). The is probably an artifact of the oligonucleo-
tide synthesis but suggests that larger peptide sequences than
the naturally occurring nine residue CDR3-like loop may be
constrained within the CTLA-4 sca¡old molecule.
Fig. 2. Structure of CTLA-4 extracellular domain. a: Nuclear magnetic resonance structure of CTLA-4 [22] showing the position of the CDR-
like loops, loop APB and the N and C terminus of CTLA-4 (b). Schematic representation of the CTLA-4 sca¡old molecule. The eight L strands
are indicated as A, AP, B, C, CP, D, E, F and G. These anti-parallel L strands constitute two L sheets. The loops connecting the L strands are
represented by a thin curved line. The natural CDR3-like loop of CTLA-4 is indicated and the loop APB is indicated as a potential alternative
permissive site on the opposite side of the CTLA-4 Ig fold to the natural binding surface. Both the Ig-type disul¢de bridge and the extra disul-
¢de bridge are also shown by the symbol SS. Adapted from [22].
Table 2
Selected heterologous RGD peptide sequences in the permissive
CDR3-like loop of CTLA-4
Clone Protein sequence
Wild-type CTLA-4 L M Y P P P Y Y L
RGD-7B: F L P R G D D Y P R R
RGD-8H: I L D R G D S Y Y
RGD-11C: V Q* G R G D S H P A I
RGD-9B: H P C R G D C L A
RGD-8E: K P D R G D Y A P
RGD-11B: T T A R G D S D K
Fibronectin V T G R G D S P A S S
The alignment of isolated clones which demonstrated binding to
KvL3 integrin. Wild-type CTLA-4 sca¡old sequence corresponding
to the CDR3 loop (L97MYPPPYYL105) is shown. The correspond-
ing 9 and 11 amino acid RGD loop substitutions (shown in bold)
for the six heterologous peptide sequences isolated, RGD-7B, 8C,
11C, 9B, 8E and 11B are shown. RGD-11C has an amber codon in-
dicated by * which when suppressed becomes a glutamine residue.
The relevant sequence of ¢bronectin responsible for binding to KvL3
integrin is also indicated.
Fig. 3. Speci¢city ELISA of speci¢c CTLA-4 sca¡old derivatives.
Speci¢city phage ELISA of CTLA-4 sca¡old derivatives on a mono-
clonal antibody to CTLA-4 (IGH310), B7-1 Ig, B7-2 Ig, KvL3 integ-
rin, BSA, CTLA-4 Ig, human IgG and baculovirus produced Fc.
Clones RGD-7B, RGD-8C, RGD-8E, RGD-9B, RGD-11B and
RGD-11C are CTLA-4 sca¡old variants presenting di¡erent RGD
peptide loops in the CDR3-like loop of CTLA-4.
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3.4. Analysis of the selected CTLA-4 RGD variants
To test the absolute speci¢city of the six di¡erent selected
CTLA-4 (RGD) clones, ELISA was performed on KvL3 in-
tegrin, BSA, B7-1 Ig, B7-2 Ig, CTLA-4 Ig, human IgG, ba-
culovirus produced-Fc and a conformational-speci¢c antibody
to CTLA-4 (Fig. 3). The clones RGD-7B, RGD-8C, RGD-
8E, RGD-9B, RGD-11B and RGD-11C were speci¢c for
KvL3 integrin with no demonstrated residual binding to B7-
1 Ig or B7-2 Ig. Furthermore, strong binding to a conforma-
tional-speci¢c antibody indicated that the underlying protein
framework and general structure of CTLA-4 appeared intact,
despite the incorporation of a heterologous peptide sequence.
To test whether RGD-7B was able to recognize integrins in
situ, we performed £ow cytometric analysis with HUVECS. It
can be seen that RGD-7B phage showed binding to HUVECS
whereas wild-type phage showed only background binding
(Fig. 4). Phage displaying wild-type CTLA-4 showed some
binding which probably represents endogenous binding to
B7 on HUVECS. This clearly demonstrates that CTLA-4
(RGD) variants can recognize cell surface integrins in their
normal context.
The expression of soluble CTLA-4 (RGD) sca¡old mole-
cules was assessed by immunoblotting and it was seen that a
homogeneous band of the expected size of 16 kDa was recov-
ered for all clones except RGD-11C which gave no protein
product (this was due to the stop codon present in this clone
which was not suppressed in the bacterial strain HB2151 (Fig.
5). The wild-type CTLA-4 sca¡old protein and the CTLA-4
variant, RGD-7B, were isolated on a larger scale from the
bacterial periplasm and puri¢ed using immobilized metal af-
¢nity chromatography. The proteins were analyzed by gel
¢ltration on a pre-calibrated Superdex 75 gel ¢ltration col-
umn. Wild-type CTLA-4 recombinant protein gave predom-
inantly two species corresponding to dimeric (approximately
30 kDa; 16.32 min) and aggregated material (11.24 min) (Fig.
6a). RGD-7B also gave dimeric (approximately 30 kDa; 16.16
min) and some aggregated material (11.31 min)(Fig. 6b), how-
ever, for RGD-7B there was an increase in the amount of
dimeric material present relative to aggregated material.
Only very low levels of monomeric protein could be detected.
This is in agreement with the recent report of Nuttall et al.
(1999) who noted that dimers were the dominant molecular
weight species particularly when there was a delay before pu-
ri¢cation of periplasmic extracts [24]. The isolated peaks were
analyzed by SDS^PAGE and it was shown that both dimers
and aggregated material could be reduced to the monomeric
form (data not shown).
Fig. 4. Binding of CTLA-4 sca¡old RGD containing clone to integ-
rins in situ. Binding of phage (5U1011 cfu/ml) displaying RGD-7B
molecule to (8.75U104 cells) human umbilical vein endothelial cells
using £ow cytometry. a: Binding can be seen with phage prepared
from RGD-7B (bold line). Phage displaying wild-type CTLA-4
showed some binding to a lower level than RGD-7B (normal line).
Empty phage containing pCES-1 showed background binding (thin
line). b: The positive control antibody LM609 also showed binding
on HUVECS.
Fig. 5. Western blot analysis of CTLA-4 (RGD) sca¡old variants.
Periplasmic preparations of the CTLA-4 (RGD) sca¡old variants in
the non-suppressor strain HB2151. Detection with anti-c-Myc anti-
body of RGD-7B, RGD-8C, RGD-8E, RGD-9B, RGD-11B, RGD-
11C* and wild-type CTLA-4 shows a product of the expected mo-
lecular weight of 16 kDa.
Fig. 6. Analysis of CTLA-4 and CTLA-4 variant RGD-7B by gel ¢ltration. a: Gel ¢ltration of metal chelate a⁄nity-puri¢ed recombinant
CTLA-4 variants on a pre-calibrated Superdex 75 column. For wild-type CTLA-4 sca¡old molecule two dominant protein species are present
corresponding to dimeric (‘#’) and aggregated material (‘*’). b: RGD-7B also gave dimeric (‘#’) and aggregated material (‘*’). Monomeric
CTLA-4 protein production is indicated by O.
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3.5. Evaluation of a potential permissive site opposite the
CDR-like loops
Graphical analysis of the CTLA-4 sca¡old molecule sug-
gested an alternative permissive site in CTLA-4 to the natural
binding surface. The CTLA-4 molecule is stabilized by two
disul¢de bridges and, as such, may be tolerant of insertion or
substitution at loops of the CTLA-4 framework opposite to
the natural CDR-like loops. The loop formed by the L strands
APB (between S14R) was chosen for investigation (Fig. 2). To
validate this loop the relatively inert sequence SGGGS was
inserted between residues S14R to give CTLA-4 (APB).
To evaluate the structural and functional integrity of this
molecule, we performed a speci¢city ELISA with phage dis-
played product on KvL3 integrin, B7-1 Ig, B7-2 Ig, BSA, anti-
CTLA-4, human IgG, baculovirus produced-Fc and CTLA-4
Ig. CTLA-4 (APB) showed binding to the conformational-spe-
ci¢c anti-CTLA-4 antibody and also showed binding to the
natural ligands B7-1 Ig and B7-2 Ig (Fig. 7). This demon-
strated that CTLA-4 (APB) was most likely folded and dis-
played correctly, and despite peptide insertion within loop
APB, remained functionally intact.
4. Discussion
We report the successful phage display of the extracellular
domain of CTLA-4. Furthermore, we describe the selection of
CTLA-4 binding variants with integrin binding activity from a
focussed repertoire and the de¢nition of an alternative per-
missive site distinct from the natural binding surface of
CTLA-4.
The expression of non-glycosylated CTLA-4 in E. coli has
been shown previously to lead to aggregation [20]. CTLA-4 is
normally a glycoprotein and mutation of the glycosylation site
(N78) leads to aggregation with an accompanying reduction in
binding activity [22]. This suggested that glycosylation is es-
sential for maintaining the monomeric status of CTLA-4.
Both mammalian cells [20] and the yeast Pichia pastoris [21]
have been used to produce glycosylated and functional mono-
mers of CTLA-4 extracellular domain. We report here that
the extracellular domain of CTLA-4 can be produced by se-
cretion from E. coli and be displayed on the surface of ¢la-
mentous phage. Furthermore it can be produced as a mixture
of soluble monomers, dimers and aggregated material. The
lack of a carbohydrate moiety on the hydrophobic BED
face of CTLA-4 probably accounts for some of the aggrega-
tion. The substitution of the hydrophobic MYPPPY loop of
CTLA-4 with a heterologous peptide, however, also shifts the
equilibrium from aggregated material towards the dimeric
form. Although both wild-type and CDR3-substituted
CTLA-4 molecules showed clear binding in soluble ELISA,
it is unclear if the active species is a dimer or the very low
level of monomer that can be detected. This suggests that it is
a combination of both the hydrophobic BED face of CTLA-4
exposed in the absence of glycosylation and the hydrophobic
MYPPPY loop that lead to signi¢cant aggregation in pro-
karyotic expression systems which has also been reported by
others. The successful display of CTLA-4 sca¡old molecules
on ¢lamentous phage has presumably limited the aggregation
and allowed the presentation of both structurally and func-
tionally intact molecules fused to the phage p3 coat protein.
The issue of whether CTLA-4 is a monomer or dimer dis-
played on phage is open to speculation and cannot easily be
resolved. If dimers are displayed then their presence, if they
are functional, could increase the selection e⁄ciency as is
often the case with dimerizing scFv antibodies. It should be
emphasized that this issue has not prevented the use of
CTLA-4 as a protein sca¡old. Furthermore, we have clearly
demonstrated that CTLA-4 repertoires can be generated from
which lead binding molecules can be isolated for further
downstream development.
We have semi-randomized the CDR3 loop of the CTLA-4
sca¡old and showed that one can select novel molecules which
bind to KvL3 integrin, by means of constrained heterologous
peptide sequences. We selected six di¡erent peptide sequences
grafted into the CDR3-like loop of the CTLA-4 sca¡old. The
dominant clone was RGD-7B, which suggests that ¢ve resi-
dues on the 3P side of the RGD motif may be preferential to
three residues indicating that a larger loop can be constrained
within the CTLA-4 than that of the natural CDR3 loop. This
may be bene¢cial in that the generation of a large extended
loop may have speci¢c applications for binding into clefts
present in enzyme active sites [25,26], and receptors, as is
the case for camel VHH antibodies. This is in contrast to
Igs from other mammals, in which antibodies are selected
for binding to larger £atter surfaces similar to those found
on the surface of proteins [25]. Indeed, structure-based mod-
eling of the extracellular domain of CTLA-4 has shown sig-
ni¢cant structural similarity with camel VHH domain antibod-
ies suggesting that loops from CTLA-4 could be grafted onto
a VHH framework and vice versa (data not shown).
Heterologous binding sequences within the CTLA-4 scaf-
fold were recovered with identity to recognized KvL3 integrin
binding peptides and also to ¢bronectin, a natural ligand of
KvL3 integrin. The clone RGD-11C showed identical £anking
residues (to the RGD motif) that exist in the natural target,
¢bronectin (Table 2), possibly indicating the relative inde-
pendence of the peptide from the sca¡old or structural con-
servation between ¢bronectin and CTLA-4 which are both
members of the Ig superfamily. The residue C-terminal to
the RGD motif in ¢bronectin is a serine residue and in three
of the selected clones (RGD-8H, RGD-11C and RGD-11B) a
serine residue is present in the equivalent position. This indi-
cates that CTLA-4 is an excellent sca¡old and has allowed the
isolation of an RGD loop, which is homologous to the ‘nat-
urally’ optimized loop within ¢bronectin. The CTLA-4 scaf-
fold derivative, RGD-9B, is directly analogous to the RGD-
Fig. 7. Evaluation of loop APB as a permissive site. Binding in
phage ELISA of CTLA-4 (APB) to anti-CTLA-4 (IGH310), B7-1 Ig,
B7-2 Ig, KvL3 integrin, BSA, CTLA-4 Ig, human IgG, baculovirus
produced Fc. CTLA-4 (APB) refers to the insertion of the sequence
SGGGS into the loop APB. Phage displaying unmodi¢ed CTLA-4
extracellular domain is shown by wild-type CTLA-4. Fab (B7-1) re-
fers to control phage displaying a Fab antibody speci¢c for B7-1.
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4C peptide isolated by the group of Ruoslahti [27], which
speci¢es an RGD determinant constrained by two disul¢de
bridges. This peptide has been reported to be highly selective
for KvL3 integrin in vivo and it could be expected that the
similarly constrained peptide within the context of the CTLA-
4 sca¡old (with the RGD motif constrained by one disul¢de
motif and also the CTLA-4 framework), will have similar
speci¢city. The equivalence between selected peptide sequen-
ces, and peptide sequences selected within the context of
CTLA-4 suggests that, in some cases, CTLA-4-derived pep-
tide loops may bind as individual peptides.
We also describe an alternative permissive site which is
separate from the natural binding surface of CTLA-4. Inser-
tion of a ¢ve residue inert peptide sequence at the loop formed
by L strands A and BP did not a¡ect binding to the natural
ligand B7. The underlying Ig framework can be assumed to be
intact as previous e¡orts to both isolate constrained peptide-
based binding ligands based on the MYPPPY motif and to
present within a permissive site of hirudisin, failed to generate
B7 binding ligands [28]. Future experiments will involve the
generation of repertoires with both an insertion and a replace-
ment randomized loop so that ligands with the desired bind-
ing properties can be selected using display technology. The
further development of this loop may allow the generation of
a new type of bispeci¢c molecule, which is analogous to the
antibody-derived M bodies described by [29].
The potential of CTLA-4 as a sca¡old molecule for the
generation of a new family of binding ligands is clear. Its
human origin means that it is less likely to elicit an immune
response than non-human binding ligands after therapeutic
administration. The current development of CTLA-4-Ig for
the treatment of host versus graft disease suggests easy engi-
neering of CTLA-4 sca¡old derivatives into immunoadhesins
[30] and also demonstrates the potential to develop novel
CTLA-4-based immunomodulatory reagents with modi¢ed
binding activity and speci¢city. Furthermore, the engineering
of multivalent, multispeci¢c molecules based on a single Ig
fold may overcome some of the di⁄culties associated with
the production of higher-order derivatives of conventional
antibodies such as diabodies and triabodies [8]. Future re-
search will also determine whether binding molecules to di-
verse molecular targets can be isolated from a large ‘single
pot’ non-biased repertoire. It will also be interesting to ex-
plore the possibility of certain target type complementarity.
The structural similarity between CTLA-4 and camel VHH
domains suggests that engineered CTLA-4 derivatives may
be suitable for binding to enzyme active sites or receptor bind-
ing pockets as is noted for camel VHH single domain anti-
bodies [25].
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